Hodgkin Lymphoma Clinical Trials in Beijing, Beijing Municipality
20 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 20 trials
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Excyte Biopharma Ltd48 enrolled1 locationNCT06565689
Recruiting
Phase 1Phase 2
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Phase 1
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.110 enrolled13 locationsNCT06219356
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in Relapse+4 more
Essen Biotech75 enrolled1 locationNCT06213636
Recruiting
Phase 1Phase 2
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled1 locationNCT06838832
Recruiting
Phase 1Phase 2
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Non-Hodgkin Lymphoma
Chinese PLA General Hospital30 enrolled3 locationsNCT06323525
Recruiting
Phase 1Phase 2
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled4 locationsNCT06925464
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
Peking University Cancer Hospital & Institute42 enrolled3 locationsNCT06313957
Recruiting
Phase 3
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd.185 enrolled1 locationNCT06170489
Recruiting
Phase 1
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Kai Hu24 enrolled1 locationNCT06822868
Recruiting
Phase 1Phase 2
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled2 locationsNCT06321289
Recruiting
Phase 2
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Refractory Classic Hodgkin LymphomaRelapsed Classic Hodgkin Lymphoma
Navy General Hospital, Beijing40 enrolled1 locationNCT06190067
Recruiting
Phase 1
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Non-Hodgkin LymphomaB-cell Lymphoma
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06180174
Recruiting
Phase 1Phase 2
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT05896046
Recruiting
Phase 1Phase 2
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Non-Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT04337606